Diseases neurologic

Zecca L, Zucca FA, Albertini A et al (2006) A proposed dual role of neuromelanin in the pathogenesis of Parkinson s disease. Neurology 67 S8—SI 1... [Pg.166]

Bonuccelli U, Del Dotto P (2006) New pharmacologic horizons in the treatment of Parkinson disease. Neurology 67 S30-S38... [Pg.166]

Rogers, SL, Farlow, MR, Doody, RS, Mohs, R, Friedhoff, LT and the Donepezil Study Group (1998) A 24-week, double blind, placebo-controlled trial of donepezil in patients with Alzheimer s disease. Neurology 50 136-145. [Pg.394]

Inflammatory conditions of the prostate Coronary and peripheral vascular disease Neurologic disorders (e.g., Parkinson s disease and multiple sclerosis)... [Pg.782]

Gagnon J., Bedard M-A., Fantini M. et al. (2002). REM sleep behavior disorder and REM sleep without atonia in Parkinson s disease. Neurology 59, 585-9. [Pg.212]

Schapira A. (2004). Excessive daytime sleepiness in Parkinson s disease. Neurology 63(8 Suppl. 3), S24-7. [Pg.220]

Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ et al. (1993). Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer s disease. Neurology, 43, 1467-1472. [Pg.282]

Farlow MR, Lahiri DK, Poirier J, Da-vignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer s disease. Neurology 1998 50 669-677. [Pg.55]

Hering, R., Petrovic, S., Mietz, E. M. et al. Extended mutation analysis and association studies of Nurrl (NR4A2) in Parkinson disease. Neurology 62 1231-1232, 2004. [Pg.664]

Huang, X., Chen, P. C. and Poole, C. APOE-epsilon2 allele associated with higher prevalence of sporadic Parkinson disease. Neurology 62 2198-2202, 2004. [Pg.665]

MacDonald, M. E., Vonsattel, J. P., Shrinidhi, J. et al. Evidence for the GluR6 gene associated with younger onset age of Huntington s disease. Neurology 53 1330-1332,1999. [Pg.666]

Carpenter, S. Proximal axonal enlargement in motor neuron disease. Neurology 18 841-851,1968. [Pg.740]

McKhann, G., Drachman, D., Folstein, M. et al. Clinical diagnosis of Alzheimer s disease report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer s Disease. Neurology 34 939-944,1984. [Pg.788]

Marek, K. L., Seibyl, J. P Zoghbi, S. S. et al. 123I-P-CIT/ SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson s disease. Neurology 46 231-237, 1996. [Pg.961]

Farlow, M.R., "Treatment Outcome of Tacrine Therapy Depends on Apolipoprotein Genotype and Gender of the Subjects with Alzheimer s Disease," Neurology, 50, 669-677 (1998). [Pg.185]

P. A. Bhaskar, S. Vanchilingam, E. A. Bhaskar, A. Devaprabhu, and R. A. Ganesan. Effect of L-dopa on visual evoked potential in patients with Parkinson s disease. Neurology 36 1119-1121 (1986). [Pg.338]

Oianow CW. (1997). Attempts to obtain neuroprotection in Parkinson s disease. Neurology. 49(suppl 1) S26-33. [Pg.484]

Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. (1995). Nonsteroidal antiinflammatory drugs in Alzheimer s disease. Neurology. 45(1) 51-55. [Pg.486]

Ambler, M.W., Trice, J., Grauerholz, J., and O Shea, P.A. (1983) The Association of Infantile Osteopetrosis and Neuronal Storage Disease. Neurology 437-441. [Pg.98]

Shaw G (2011) New evidence for association of pesticides with Parkinson disease. Neurology Today 11 16-21... [Pg.394]

Tlal LJ, Forreest M, Loft FI, Lu-25-109, a muscarinic agent, fails to improve cognition in Alzheimers disease, Neurology 54 421-426, 2000. [Pg.420]

Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL et al. Recombinant human acid [alpha]-glucosidase major clinical benefits in infantile-onset Pompe disease. Neurology 2007 68(2) 99-109. [Pg.488]

K. A. Frey, M.R. Kilbourn, In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer s disease. Neurology 52 (1999) 691-699. [Pg.82]

N.M. Kemppainen, S. Aalto, I.A. Wilson, K. Nagren, S. Helin, A. Bruck, V. Oikonen, M. Kailajarvi, M. Scheinin, M. Viitanen, R. Parkkola, J.O. Rinne, Voxel-based analysis of amyloid ligand [ C]PIB uptake in Alzheimer disease, Neurology 67 (2006) 1575-1580. [Pg.83]

Papilloma. A benign epithelial neoplasm producing finger-like or verrucous projections from the epithelial surface. Parakeratosis. Persistence of the nuclei of the keratinocytes into the stratum corneum (horny layer) of the skin. Parakeratosis is normal in the epithelium of true mucous membrane of the mouth and vagina. Parkinson s disease. Neurological disorder characterized by hypokinesia, tremor, and muscular rigidity. [Pg.573]

Hutton IT, Roller WC, Ahlskog IE, et ah Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson s disease. Neurology 1996 464 062-1065. [Pg.174]

Guttman M, International Pramipexole-Bromocriptine Study Group. Double blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson disease. Neurology 1997,49 1060-1063. [Pg.1014]

Baron JA Cigarette smoking and Parkinson s disease. Neurology 36 1490-1496, 1986... [Pg.592]

McCeer PL, Rogers J Antiinflammatory agents as a therapeutic approach to Alzheimer s disease. Neurology 42 447-448, 1992 McCeer PL, McCeer EG, Rogers J, et al Antiinflammatory drugs and Alzheimer s disease. Lancet 335 1037, 1990... [Pg.694]

Spagnoh A, Lucca U, Menasce G Long-term acetyl-L-carnitine treatment in Alzheimer s disease. Neurology 41 1726-1732, 1991... [Pg.748]

C. Cardellach, M. J. Marti, J. Pemandez-Sola, C. Marin, J. B. Hoeck, E. Tolosa and A. Urbano-Marquez, Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson s disease. Neurology, 1993,43, 2258-2262. [Pg.152]

W. C. KoIIer, E. Tolosa (1998). Current and emerging drug therapies in the treatment of Parkinson s disease. Neurology 50 (Supplement 6) 1-65. [Pg.303]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...